For important risk and disclaimer information, Click here.
|
James Miehls| Managing Director
|
|
|
|
(614) 657-8398
|
Overview
StromaGenesis is a pre-revenue biotechnology company seeking to raise $15 million of equity to launch novel molecular diagnostic tests to improve cancer patient outcomes
Leveraging assets that are the product of over 18 years of academic work to develop
-proprietary algorithm for a more precise prostate cancer prognosis
-tissue-based immunoassay to predict therapy response in multiple solid tumors (breast, colon, prostate, glioblastoma, etc.)
-tissue-based and blood-based immunoassay as companion diagnostic test for multiple solid tumors
Opportunity
- Current unmet need for more cancer diagnostics to provide more precise cancer patient management and treatment
- Prostate Cancer Diagnostics. Scope includes preliminary and confirmatory testing and ultra-sound based diagnostics, as well as molecular diagnostics (2022 Market Size $4.1Bn, CAGR 13%)
- Oncology Companion Diagnostics. Scope includes immunohistochemistry and next-generation sequencing, multiple cancer types (Market Size $3.2Bn, CAGR 13%)
- Oncology Molecular Diagnostics. Scope includesinstruments and reagents, multiple cancer and molecule types (Market Size $3.7Bn, CAGR 15%)
- Molecular genetic diagnostic companies, have high TTV/Revenue (4-28x)
- Low COGS, high sales prices and expected profitability
Solution/Strategy
- Molecular diagnostic test algorithm
- Superior precision compared to incumbent technology in four independent patient populations (n= 487 patients)
- Analysis by key opinion leaders shows unmet need and testing opportunity
- Clinical trial materials accrued
- Solid “moat” of comprehensive issued patents (USA and international – UK, EU, Canada, Australia, Japan)
StromaGenesis Leadership
Richard Pestell, AO., MD., PhD, MBA, Founder & CEO
- Relevant start-up experience: founded/funded ProstaGene, LightSeed, EcoGenome (and sold ProstaGene, 2018)
- Inventor of patents
- Director of two NCI Cancer Centers (2002-2016)
- Director Lombardi Cancer Center, Georgetown University
- Director Sidney Kimmel Cancer Center, Thomas Jefferson University
- Oversaw >120 clinical trials (phase 1, 2, 3)
- Established Phase 1 program.
- Current examiner of NCI designated Cancer Centers
- Chairman, Department of Oncology, Georgetown University (2002)
- Executive Vice President Thomas Jefferson University (2014)
- annual budget of $5.6B, eleven hospitals, 30,000 employees
- World ranked Oncology Research
- (Google Scholar, #1 cell cycle, #5 prostate, #13 breast cancer)
- >600 papers, >98,000 citations, H index 158
- Advisor/Reviewer for NCI Cancer Centers, MD Anderson Breast Cancer
Specific Risks
- Early-stage company – limited financial history, assets and cash flows
- Liquidity – insufficient capital to acquire patents and develop and/or market products
- Technology – new and/or preferred technologies may enter market; infringement on patents and/or trade secrets
- Key person – lightly-staffed and fund expertise is concentrated in a few key executives
- Competitive – Existing and/or new entrants, some with deep pockets and global operations, could develop and/or expand to compete in StromaGenesis’ markets
- Regulatory – new legislation and/or changes in regulation could negatively impact operations and/or costs
- Private securities are speculative, illiquid, and carry a high degree of risk – including the loss of the entire investment